A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.

A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
Skin Therapy Lett. 2017 Jan;22(1):1-6
Authors: Tong Y, Peranteau AJ, Nawas Z, Tyring SK
Abstract
Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia that affects 2-3% of the population. Interleukin (IL)-17 signaling has a central role in its pathogenesis. Brodalumab is a monoclonal antibody that neutralizes IL-17 receptor type A. Brodalumab is highly effective in the reversal of psoriatic phenotype and gene expression patterns.
PMID: 28122092 [PubMed - in process]

Source: Skin Therapy Letter - December 31, 2016 Category: Dermatology Authors: Tong Y, Peranteau AJ, Nawas Z, Tyring SK Tags: Skin Therapy Lett Source Type: research